J Lung Cancer.  2006 Jun;5(1):47-50. 10.6058/jlc.2006.5.1.47.

A Case of Pulmonary Thromboembolism Developed during Chemotherapy with Gemcitabine and Cisplatin for NonsmallCell Lung Cancer : A case report

• Kim KS
• Chung JW
• Jeong JP
• Oh IJ
• Kim SO
• Son JG
• Kim YI
• Lim SC
• Kim YC
• Park KO

• KMID: 1881526
• DOI: http://doi.org/10.6058/jlc.2006.5.1.47

Abstract

Lung cancer patients have increased risk of thromboembolism (TE) due to various factors such as by hypercoagulability, tumor thrombosis, decrease of ambulation, and chemotherapy etc. Among these factors, chemotherapy associated TEs have been reported, although the causes and pathomechanisms of TEs were not clear. Recently, reports proposed the potential role of platelets in endothelial damage by the chemotherapeutic agents. We have experienced a case of pulmonary TE after systemic chemotherapy with gemcitabine and cisplatin. The patient complained aggravated exertional dyspnea after chemotherapy and diagnosed as pulmonary TE by computerized tomogram. After anticoagulation and interruption of the chemotherapy, improvement of exertional dyspnea and resolution of the pulmonary TE were observed

Keyword

Gemcitabine; Thromboembolism; Lung cancer

MeSH Terms

Cisplatin*
Drug Therapy*
Dyspnea
Humans
Lung Neoplasms*
Lung*
Pulmonary Embolism*
Thromboembolism
Thrombophilia
Thrombosis
Walking
Cisplatin

Figure

• 

  Fig. 1. Chest computed tomogram obtained on initial visit. 5 cm diameter necrotic mass and mediastinal lymphadenopathy were observed.

• 

  Fig. 2. Chest computed tomogram obtained after 3 cycles of gemcitabine and cisplatin chemotherapy showed thrombi in right main pulmonary artery.

• 

  Fig. 3. Chest computed tomogram obtained 6 months after anticoagulation therapy showing resolution of thrombi in the right main pulmonary artery.

Reference

1.Nadir Y., Hoffman R., Brenner B, et al. Drug-related thrombosis in hematologic malignancies. Ref Clin Exp Hematol. 2004. 8:E4.

2.Kuenen BC., Rosen L., Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002. 20:1657–1667. ,.

3.Holmgren L., O'Reilly MS., Folkman J. Dormancy of micro. metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995. 1:149–153.

4.Dvorak HF., Brown LF: Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995. 146:1029–1039.

5.Carmeliet P: Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000. 407:249–257.

6.Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995. 1:27–31.

7.Engels K: Fox SB., Harris AL. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. EXS. 1997. 79:113–156.

8.Abulafia 0., Triest WE., Sherer DM. Angiogenesis in malignancies of the female genital tract. Gynecol Oncol. 1999. 72:220–231.

9.Seo Y., Baba H., Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000. 88:2239–2245.

10.Shih CH: Ozawa S., Ando N, et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2000. 6:1161–1168.

11.Takanami I., Tanaka F., Hashizume T, et al. Vascular endothelial growth factor and ks receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 1997. 17:2811–2814.

12.Benjamin LE. The controls of microvascular survival. Cancer Metastasis Rev. 2000. 19:75–81.

13.Kuenen BC., Levi M., Meijers JC, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin: gemcitabine: and the angiogenesis inhibitor SU5416. J Clin Oncol. 2003. 21:2192–2198.

14.Numico G., Garrone 0., Doniovanni V, et al. Prostpective evaluation of major vascular events in patients with non small cell lung carcinoma treated with cisplalin and gemcitabine. Cancer. 2005. 103:994–999.

15.Crino L: Scagliotti G., Marangolo M, et al. Cisplatin-Gemcitabine combination in advanced non small cell lung cancer: a phase II study. J Clin Oncol. 1997. 15:297–303.

16.Rosen P., Kabbinavar F., Figlin R, et al. A phase I/II trial and pharmacokinetic study of SU5416 in combination with paclitaxel/carboplatin. Proc Am Soc Clin Oncol. 2001. 20:98a. (abstr 389).

17.Schiller JH: Harrington D: Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002. 10(346):92–98.